Sign in

    Taylor Hanley • JPMorgan Chase & Co.

    Taylor Hanley's questions to Regeneron Pharmaceuticals Inc (REGN) leadership

    Taylor Hanley's questions to Regeneron Pharmaceuticals Inc (REGN) leadership • Q4 2024

    Question

    Taylor Hanley, on behalf of Chris Schott at JPMorgan, asked about the strategy for balancing operating expense investments across the late-stage pipeline and the potential for partnering on programs.

    Answer

    CEO Dr. Leonard Schleifer emphasized that R&D is the primary capital allocation priority, highlighting the company's R&D productivity. He confirmed that Regeneron maintains flexibility and an open mind about partnering programs to best allocate resources, rather than using fixed spending quotas.

    Ask Fintool Equity Research AI

    Taylor Hanley's questions to Regeneron Pharmaceuticals Inc (REGN) leadership • Q3 2024

    Question

    Taylor Hanley of JPMorgan Chase & Co. asked about Regeneron's strategy for EYLEA following a biosimilar launch, levers to accelerate conversion to EYLEA HD, and the company's broader pricing strategy for the franchise.

    Answer

    President and CEO Dr. Leonard Schleifer stated that EYLEA is a trusted product with significant brand stickiness due to its long-term safety and performance record. He emphasized that EYLEA HD is a differentiated product and the company will continue to educate physicians on its benefits, including compelling long-term data. Dr. Schleifer acknowledged the competitive landscape but expressed confidence in Regeneron's ability to compete effectively.

    Ask Fintool Equity Research AI